SVCM
SRPT icon

Saturn V Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

Saturn V Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-118,401
Closed -$14.4M – 25
2023
Q3 		$14.4M Buy
118,401
+64,406
+119% +$7.28M 6.01% 8
2023
Q2 		$6.18M Buy
+53,995
New +$6.96M 3.43% 15

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Saturn V Capital Management's SRPT Position: Q4 2023 in Review

Saturn V Capital Management sold out of Sarepta Therapeutics (SRPT) in Q4 2023, closing a stake of 118,401 shares — an estimated $14.4M sold.

Saturn V Capital Management first reported a position in SRPT in Q2 2023 and held it in 2 quarters. The position peaked at $14.4M in Q3 2023. 395 funds tracked by Wall St. Rank hold SRPT as of Q4 2023.

  • Saturn V Capital Management reported no remaining Sarepta Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Saturn V Capital Management sold 118,401 Sarepta Therapeutics shares in Q4 2023, an estimated $14.4M.
  • Saturn V Capital Management first reported a position in Sarepta Therapeutics in Q2 2023 and held it in 2 quarters.
  • Saturn V Capital Management's Sarepta Therapeutics position peaked at $14.4M in Q3 2023.
  • 395 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2023.

Based on Saturn V Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.